Cargando…

Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75

Aquaporin-4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is a rare but often severe autoimmune disease with median onset around 40 years of age. We report characteristics of three very-late-onset NMOSD (including complete NMO) patients >75 years of age, in whom this...

Descripción completa

Detalles Bibliográficos
Autores principales: Krumbholz, Markus, Hofstadt-van Oy, Ulrich, Angstwurm, Klemens, Kleiter, Ingo, Jarius, Sven, Paul, Friedemann, Aktas, Orhan, Buchholz, Grete, Kern, Peter, Straube, Andreas, Kümpfel, Tania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441737/
https://www.ncbi.nlm.nih.gov/pubmed/25957640
http://dx.doi.org/10.1007/s00415-015-7766-8
_version_ 1782372816275898368
author Krumbholz, Markus
Hofstadt-van Oy, Ulrich
Angstwurm, Klemens
Kleiter, Ingo
Jarius, Sven
Paul, Friedemann
Aktas, Orhan
Buchholz, Grete
Kern, Peter
Straube, Andreas
Kümpfel, Tania
author_facet Krumbholz, Markus
Hofstadt-van Oy, Ulrich
Angstwurm, Klemens
Kleiter, Ingo
Jarius, Sven
Paul, Friedemann
Aktas, Orhan
Buchholz, Grete
Kern, Peter
Straube, Andreas
Kümpfel, Tania
author_sort Krumbholz, Markus
collection PubMed
description Aquaporin-4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is a rare but often severe autoimmune disease with median onset around 40 years of age. We report characteristics of three very-late-onset NMOSD (including complete NMO) patients >75 years of age, in whom this diagnosis initially seemed unlikely because of their age and age-associated concomitant diseases, and briefly review the literature. All three patients, aged 79, 82 and 88 years, presented with a spinal cord syndrome as the first clinical manifestation of AQP4-Ab-positive NMOSD. They all had severe relapses unless immunosuppressive therapy was initiated, and one untreated patient died of a fatal NMOSD course. Two patients developed side effects of immunosuppression. We conclude that a first manifestation of NMOSD should be considered even in patients beyond the age of 75 years with a compatible syndrome, especially longitudinally extensive myelitis. Early diagnosis and treatment are feasible and highly relevant. Special attention is warranted in the elderly to recognize adverse effects of immunosuppressive therapies as early as possible.
format Online
Article
Text
id pubmed-4441737
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-44417372015-05-27 Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75 Krumbholz, Markus Hofstadt-van Oy, Ulrich Angstwurm, Klemens Kleiter, Ingo Jarius, Sven Paul, Friedemann Aktas, Orhan Buchholz, Grete Kern, Peter Straube, Andreas Kümpfel, Tania J Neurol Short Commentary Aquaporin-4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is a rare but often severe autoimmune disease with median onset around 40 years of age. We report characteristics of three very-late-onset NMOSD (including complete NMO) patients >75 years of age, in whom this diagnosis initially seemed unlikely because of their age and age-associated concomitant diseases, and briefly review the literature. All three patients, aged 79, 82 and 88 years, presented with a spinal cord syndrome as the first clinical manifestation of AQP4-Ab-positive NMOSD. They all had severe relapses unless immunosuppressive therapy was initiated, and one untreated patient died of a fatal NMOSD course. Two patients developed side effects of immunosuppression. We conclude that a first manifestation of NMOSD should be considered even in patients beyond the age of 75 years with a compatible syndrome, especially longitudinally extensive myelitis. Early diagnosis and treatment are feasible and highly relevant. Special attention is warranted in the elderly to recognize adverse effects of immunosuppressive therapies as early as possible. Springer Berlin Heidelberg 2015-05-10 2015 /pmc/articles/PMC4441737/ /pubmed/25957640 http://dx.doi.org/10.1007/s00415-015-7766-8 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Commentary
Krumbholz, Markus
Hofstadt-van Oy, Ulrich
Angstwurm, Klemens
Kleiter, Ingo
Jarius, Sven
Paul, Friedemann
Aktas, Orhan
Buchholz, Grete
Kern, Peter
Straube, Andreas
Kümpfel, Tania
Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
title Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
title_full Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
title_fullStr Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
title_full_unstemmed Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
title_short Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
title_sort very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
topic Short Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441737/
https://www.ncbi.nlm.nih.gov/pubmed/25957640
http://dx.doi.org/10.1007/s00415-015-7766-8
work_keys_str_mv AT krumbholzmarkus verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT hofstadtvanoyulrich verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT angstwurmklemens verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT kleiteringo verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT jariussven verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT paulfriedemann verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT aktasorhan verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT buchholzgrete verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT kernpeter verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT straubeandreas verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75
AT kumpfeltania verylateonsetneuromyelitisopticaspectrumdisorderbeyondtheageof75